Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer
Journal of Clinical Oncology (JCO) Podcast · Geoffrey R. Oxnard
April 20, 20156m 54s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A meta-analysis of 7 randomized trials comparing EGFR kinase inhibitors to chemotherapy for advanced EGFR-mutant lung cancer has shown that some populations gain greater benefit from targeted therapy – namely never-smokers, woman, and tumor harboring exon 19 deletions.